157 related articles for article (PubMed ID: 8244180)
21. Intraperitoneal interferon-alpha in residual ovarian carcinoma: a phase II gynecologic oncology group study.
Berek JS; Markman M; Stonebraker B; Lentz SS; Adelson MD; DeGeest K; Moore D
Gynecol Oncol; 1999 Oct; 75(1):10-4. PubMed ID: 10502418
[TBL] [Abstract][Full Text] [Related]
22. Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-up.
Morgan RJ; Braly P; Cecchi G; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Parker P; Stein A; Cho J; Smith E; Coluzzi P; Najera L; Johnson D; Womack E; Doroshow JH
Gynecol Oncol; 1999 Dec; 75(3):419-26. PubMed ID: 10600300
[TBL] [Abstract][Full Text] [Related]
23. Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancer.
Markman M; Reichman B; Hakes T; Lewis JL; Jones W; Rubin S; Barakat R; Curtin J; Almadrones L; Hoskins W
J Clin Oncol; 1992 Sep; 10(9):1479-84. PubMed ID: 1517791
[TBL] [Abstract][Full Text] [Related]
24. New options for the treatment of advanced ovarian cancer.
Dunton CJ
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-2-S5-11. PubMed ID: 9122739
[TBL] [Abstract][Full Text] [Related]
25. Intraperitoneal chemotherapy in ovarian cancer: an update.
Runowicz CD
Cancer J; 2008; 14(1):7-9. PubMed ID: 18303475
[TBL] [Abstract][Full Text] [Related]
26. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for the treatment of advanced primary and recurrent ovarian cancer.
Sugarbaker PH
Curr Opin Obstet Gynecol; 2009 Feb; 21(1):15-24. PubMed ID: 19124999
[TBL] [Abstract][Full Text] [Related]
27. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
Ozols RF
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247
[TBL] [Abstract][Full Text] [Related]
28. Intraperitoneal chemotherapy.
Schneider JG
Obstet Gynecol Clin North Am; 1994 Mar; 21(1):195-212. PubMed ID: 8015764
[TBL] [Abstract][Full Text] [Related]
29. Salvage intraperitoneal mitoxantrone therapy of ovarian cancer: influence of increasing the volume of treatment.
Markman M; Hakes T; Reichman B; Rubin S; Curtin J; Barakat R; Jones W; Lewis JL; Almadrones L; Hoskins W
Gynecol Oncol; 1993 May; 49(2):185-9. PubMed ID: 8504986
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
ten Bokkel Huinink W; Carmichael J; Armstrong D; Gordon A; Malfetano J
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
[TBL] [Abstract][Full Text] [Related]
31. Salvage weekly paclitaxel in recurrent ovarian cancer.
Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
[TBL] [Abstract][Full Text] [Related]
32. Five-year survival after second-line cisplatin-based intraperitoneal chemotherapy for advanced ovarian cancer.
Recio FO; Piver MS; Hempling RE; Driscoll DL
Gynecol Oncol; 1998 Mar; 68(3):267-73. PubMed ID: 9570979
[TBL] [Abstract][Full Text] [Related]
33. Intraperitoneal therapy for ovarian cancer: a treatment ready for prime time.
Armstrong DK; Brady MF
J Clin Oncol; 2006 Oct; 24(28):4531-3. PubMed ID: 17008690
[No Abstract] [Full Text] [Related]
34. Phase II trial of intraperitoneal cisplatin and mitoxantrone in patients with persistent ovarian cancer.
Husain A; Sabbatini P; Spriggs D; Fennelly D; Aghajanian C; Barakat R; Curtin J; Venkatraman E; Hoskins W; Markman M
Gynecol Oncol; 1999 Apr; 73(1):96-101. PubMed ID: 10094887
[TBL] [Abstract][Full Text] [Related]
35. Intraperitoneal chemotherapy: standard of care for patients with minimal residual stage III ovarian cancer?
Tummala MK; Alagarsamy S; McGuire WP
Expert Rev Anticancer Ther; 2008 Jul; 8(7):1135-47. PubMed ID: 18588458
[TBL] [Abstract][Full Text] [Related]
36. Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer.
Gadducci A; Iacconi P; Cosio S; Fanucchi A; Cristofani R; Riccardo Genazzani A
Gynecol Oncol; 2000 Dec; 79(3):344-9. PubMed ID: 11104603
[TBL] [Abstract][Full Text] [Related]
37. Ifosfamide/mesna as salvage therapy in platinum pretreated ovarian cancer patients--long-term results of a phase II study.
Baur M; Fazeny-Doerner B; Hudec M; Sevelda P; Salzer H; Dittrich C
Cancer Invest; 2006 Feb; 24(1):22-7. PubMed ID: 16466988
[TBL] [Abstract][Full Text] [Related]
38. Critical evaluation of secondary cytoreduction in recurrent ovarian cancer.
Munkarah AR; Coleman RL
Gynecol Oncol; 2004 Nov; 95(2):273-80. PubMed ID: 15491746
[TBL] [Abstract][Full Text] [Related]
39. Diagnosis and management of epithelial ovarian cancer.
Bhoola S; Hoskins WJ
Obstet Gynecol; 2006 Jun; 107(6):1399-410. PubMed ID: 16738170
[TBL] [Abstract][Full Text] [Related]
40. Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up.
Morgan RJ; Braly P; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Najera L; Johnson D; Doroshow JH
Gynecol Oncol; 2000 Jun; 77(3):433-8. PubMed ID: 10831355
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
